Table 1.
Clinical baseline characteristics in the development and validation cohorts.
| Development cohort |
Validation cohort |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Variables |
Total |
CRA group |
Control group |
P value* |
Total |
CRA group |
Control group |
P value* |
P value# |
| (n = 223) | (n = 101) | (n = 122) | (n = 97) | (n = 44) | (n = 53) | ||||
| Sex, n (%) | 0.073 | 0.839 | 0.759 | ||||||
| Male | 120 (53.81) | 61 (60.40) | 59 (48.36) | 54 (55.67) | 24 (54.55) | 30 (56.60) | |||
| Female | 103 (46.19) | 40 (39.60) | 63 (51.64) | 43 (44.33) | 20 (45.45) | 23 (43.40) | |||
| Age, years | 51.24 ± 12.65 | 59.23 ± 12.12 | 44.63 ± 8.67 | ＜0.001 | 54.10 ± 10.93 | 60.39 ± 12.49 | 48.89 ± 5.53 | ＜0.001 | 0.099 |
| BMI, kg/m2 | 24.87 ± 3.80 | 24.67 ± 3.93 | 25.03 ± 3.70 | 0.421 | 24.82 ± 4.07 | 24.81 ± 4.41 | 24.82 ± 3.80 | 0.879 | 0.590 |
| HBP, n (%) | 0.007 | 0.199 | 0.149 | ||||||
| Yes | 54 (24.22) | 33 (32.67) | 21 (17.21) | 31 (31.96) | 17 (38.64) | 14 (26.42) | |||
| No | 169 (75.78) | 68 (67.33) | 101 (82.79) | 66 (68.04) | 27 (61.36) | 39 (73.58) | |||
| ALB, g/L | 44.28 ± 4.26 | 41.58 ± 4.45 | 46.52 ± 2.39 | ＜0.001 | 44.71 ± 4.16 | 41.50 ± 3.86 | 47.38 ± 1.91 | ＜0.001 | 0.130 |
| TC, mmol/L | 4.82 ± 0.98 | 4.51 ± 0.96 | 5.09 ± 0.92 | ＜0.001 | 4.98 ± 0.92 | 4.71 ± 0.93 | 5.20 ± 0.86 | 0.013 | 0.185 |
| HDL-C, mmol/L | 1.31 ± 0.38 | 1.21 ± 0.34 | 1.40 ± 0.39 | ＜0.001 | 1.24 ± 0.32 | 1.15 ± 0.30 | 1.31 ± 0.31 | 0.008 | 0.133 |
| LDL-C, mmol/L | 3.07 ± 0.90 | 2.81 ± 0.82 | 3.29 ± 0.90 | ＜0.001 | 3.18 ± 0.84 | 2.96 ± 0.94 | 3.36 ± 0.72 | 0.019 | 0.307 |
| TG, mmol/L | 1.36 ± 0.79 | 1.31 ± 0.64 | 1.39 ± 0.90 | 0.713 | 1.63 ± 1.20 | 1.88 ± 1.59 | 1.43 ± 0.70 | 0.282 | 0.065 |
| FBG, mmol/L | 4.80 ± 0.86 | 4.93 ± 0.92 | 4.69 ± 0.79 | ＜0.001 | 5.23 ± 1.23 | 5.25 ± 1.26 | 5.22 ± 1.22 | 0.747 | 0.020 |
| WBC, 109/L | 5.96 ± 1.47 | 5.99 ± 1.57 | 5.94 ± 1.38 | 0.889 | 5.86 ± 1.47 | 5.96 ± 1.62 | 5.78 ± 1.34 | 0.747 | 0.367 |
| NEUT, 109/L | 3.48 ± 1.18 | 3.46 ± 1.33 | 3.50 ± 1.05 | 0.405 | 3.34 ± 0.98 | 3.27 ± 0.89 | 3.40 ± 1.05 | 0.712 | 0.398 |
| LYM, 109/L | 2.00 ± 0.69 | 1.93 ± 0.52 | 2.09 ± 0.85 | 0.160 | 1.99 ± 0.65 | 1.89 ± 0.54 | 2.10 ± 0.76 | 0.305 | 0.736 |
| MONO, 108/L | 3.82 ± 1.10 | 4.18 ± 1.10 | 3.53 ± 1.01 | ＜0.001 | 3.48 ± 1.10 | 3.90 ± 1.13 | 3.13 ± 0.09 | ＜0.001 | 0.011 |
| RBC, 1012/L | 4.57 ± 0.49 | 4.45 ± 0.46 | 4.68 ± 0.49 | 0.003 | 4.62 ± 0.59 | 4.37 ± 0.63 | 4.83 ± 0.46 | ＜0.001 | 0.506 |
| HGB, g/L | 139.78 ± 15.83 | 136.51 ± 15.21 | 142.48 ± 15.88 | 0.005 | 139.24 ± 16.94 | 134.48 ± 15.55 | 143.19 ± 17.17 | 0.005 | 0.738 |
| Number of polyps | 3.59 ± 2.48 | 2.77 ± 2.46 | 0.068 | ||||||
| Diameter max, cm | 1.23 ± 0.67 | 1.48 ± 0.87 | 0.098 | ||||||
CRA, colorectal adenoma; BMI, body mass index; HBP, history of high blood pressure; ALB, albumin; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TG, triglyceride; FBG, fasting blood-glucose; WBC, white blood cell count; NEUT, neutrophil count; LYM, lymphocyte count; MONO, monocyte count; RBC, red blood cell count; HGB, hemoglobin. “Diameter max” refers to the maximum diameter of the polyps.
Data were expressed as n (%) or mean ± standard deviation.
P value* for difference between the CRA and Control groups in the development and validation cohorts, respectively.
P value# for difference between the development cohort and validation cohort.